Given the key role of Polη in TLS and cisplatin chemoresistance of ovarian cancer stem cells (95), targeting Polη O-GlcNAcylation could be a chemotherapy-enhancing strategy in ovarian cancer treatment. This evidence concerns the gene POLH and ovarian carcinoma.